REMUS (REMUS) fundamentals
REMUS is a listed company, part of the Trading sector, listed on the NSE as REMUS (ISIN INE0O5T01011). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What REMUS does
Remus Pharmaceuticals Limited is an India-based company, which is engaged in marketing and distribution of finished formulations of pharmaceutical drugs. The Company also deals in active pharmaceutical ingredients (APIs). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. It offers a range of pharmaceutical formulations and products manufactured on contract manufacturing and on a loan license basis. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension and tablet. The Company offers its products in various therapeutic categories, such as oncology, cardiovascular, anti-diabetic, central nervous system (CNS), immunosuppressants, anti-biotic - antibacterial and dermatology.
Valuation and market data
| Last close | ₹885.00 |
|---|---|
| Market capitalisation | ₹521 crore |
| Enterprise value | ₹543 crore |
| P/E (TTM) | 0.00 |
| Price to book | 1.85 |
| Price to sales (TTM) | 0.00 |
| Book value per share | ₹479.55 |
| Dividend yield | 11.30% |
| Sector | Trading |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹860 crore | ₹59 crore | ₹46 crore | 0.00 |
| Mar 2025 | ₹625 crore | ₹47 crore | ₹38 crore | 65.21 |
| Mar 2024 | ₹218 crore | ₹32 crore | ₹26 crore | 152.01 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 71.0% |
|---|---|
| Foreign institutions (FII) | 5.3% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.8% |
| Retail and others | 22.9% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.